Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ranolazine Extended-release Tablets in Healthy Chinese Subjects
NCT07054255Phase 1Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ranolazine in Angina Pectoris (AP) (2 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-Time Curve from time zero to the last measurable concentration and 1 more. Started Sep 2020; status: completed.
02
Drugs
ranolazine
03
Conditions
Angina Pectoris (AP)
Beyond the preview
Go deeper on NCT07054255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07054255.